169 related articles for article (PubMed ID: 22492660)
1. A simulation study of finite-sample properties of marginal structural Cox proportional hazards models.
Westreich D; Cole SR; Schisterman EF; Platt RW
Stat Med; 2012 Aug; 31(19):2098-109. PubMed ID: 22492660
[TBL] [Abstract][Full Text] [Related]
2. A comparison of methods to estimate the hazard ratio under conditions of time-varying confounding and nonpositivity.
Naimi AI; Cole SR; Westreich DJ; Richardson DB
Epidemiology; 2011 Sep; 22(5):718-23. PubMed ID: 21747286
[TBL] [Abstract][Full Text] [Related]
3. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.
Cole SR; Jacobson LP; Tien PC; Kingsley L; Chmiel JS; Anastos K
Am J Epidemiol; 2010 Jan; 171(1):113-22. PubMed ID: 19934191
[TBL] [Abstract][Full Text] [Related]
4. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.
Cole SR; Hudgens MG; Tien PC; Anastos K; Kingsley L; Chmiel JS; Jacobson LP
Am J Epidemiol; 2012 Mar; 175(5):381-90. PubMed ID: 22302074
[TBL] [Abstract][Full Text] [Related]
5. Ensemble learning of inverse probability weights for marginal structural modeling in large observational datasets.
Gruber S; Logan RW; Jarrín I; Monge S; Hernán MA
Stat Med; 2015 Jan; 34(1):106-17. PubMed ID: 25316152
[TBL] [Abstract][Full Text] [Related]
6. Analysis approaches to address treatment nonadherence in pragmatic trials with point-treatment settings: a simulation study.
Hossain MB; Mosquera L; Karim ME
BMC Med Res Methodol; 2022 Feb; 22(1):46. PubMed ID: 35172746
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of conventional and marginal structural Cox model estimators: a simulation study.
Xiao Y; Abrahamowicz M; Moodie EE
Int J Biostat; 2010; 6(2):Article 13. PubMed ID: 21969997
[TBL] [Abstract][Full Text] [Related]
8. Time scale and adjusted survival curves for marginal structural cox models.
Westreich D; Cole SR; Tien PC; Chmiel JS; Kingsley L; Funk MJ; Anastos K; Jacobson LP
Am J Epidemiol; 2010 Mar; 171(6):691-700. PubMed ID: 20139124
[TBL] [Abstract][Full Text] [Related]
9. Robust versus consistent variance estimators in marginal structural Cox models.
Enders D; Engel S; Linder R; Pigeot I
Stat Med; 2018 Oct; 37(24):3455-3470. PubMed ID: 29888510
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models.
Kyle RP; Moodie EE; Klein MB; Abrahamowicz M
Am J Epidemiol; 2016 Aug; 184(3):249-58. PubMed ID: 27416840
[TBL] [Abstract][Full Text] [Related]
12. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
Cole SR; Hernán MA; Robins JM; Anastos K; Chmiel J; Detels R; Ervin C; Feldman J; Greenblatt R; Kingsley L; Lai S; Young M; Cohen M; Muñoz A
Am J Epidemiol; 2003 Oct; 158(7):687-94. PubMed ID: 14507605
[TBL] [Abstract][Full Text] [Related]
13. Structural accelerated failure time models for survival analysis in studies with time-varying treatments.
Hernán MA; Cole SR; Margolick J; Cohen M; Robins JM
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):477-91. PubMed ID: 15660442
[TBL] [Abstract][Full Text] [Related]
14. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
Hernán MA; Brumback B; Robins JM
Epidemiology; 2000 Sep; 11(5):561-70. PubMed ID: 10955409
[TBL] [Abstract][Full Text] [Related]
15. Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model.
Cole SR; Edwards JK; Westreich D; Lesko CR; Lau B; Mugavero MJ; Mathews WC; Eron JJ; Greenland S;
Biom J; 2018 Jan; 60(1):100-114. PubMed ID: 29076182
[TBL] [Abstract][Full Text] [Related]
16. Validating an approach to overcome the immeasurable time bias in cohort studies: a real-world example and Monte Carlo simulation study.
Oh IS; Jeong HE; Lee H; Filion KB; Noh Y; Shin JY
Int J Epidemiol; 2023 Oct; 52(5):1534-1544. PubMed ID: 37172269
[TBL] [Abstract][Full Text] [Related]
17. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
Charalambous S; Grant AD; Innes C; Hoffmann CJ; Dowdeswell R; Pienaar J; Fielding KL; Churchyard GJ
AIDS; 2010 Nov; 24 Suppl 5(0 5):S5-13. PubMed ID: 21079429
[TBL] [Abstract][Full Text] [Related]
18. Marginal structural models with latent class growth analysis of treatment trajectories: Statins for primary prevention among older adults.
Diop A; Sirois C; Guertin JR; Schnitzer ME; Candas B; Cossette B; Poirier P; Brophy J; Mésidor M; Blais C; Hamel D; Tadrous M; Lix L; Talbot D
Stat Methods Med Res; 2023 Nov; 32(11):2207-2225. PubMed ID: 37750253
[TBL] [Abstract][Full Text] [Related]
19. Simulation from a known Cox MSM using standard parametric models for the g-formula.
Young JG; Tchetgen Tchetgen EJ
Stat Med; 2014 Mar; 33(6):1001-14. PubMed ID: 24151138
[TBL] [Abstract][Full Text] [Related]
20. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy.
Barrón Y; Cole SR; Greenblatt RM; Cohen MH; Anastos K; DeHovitz JA; Delapenha R; Gange SJ
AIDS; 2004 Jul; 18(11):1579-84. PubMed ID: 15238776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
